

Klaus F Rabe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5755443/publications.pdf>

Version: 2024-02-01

622
papers

56,117
citations

1793

106
h-index

1680

220
g-index

693
all docs

693
docs citations

693
times ranked

40027
citing authors

#	ARTICLE	IF	CITATIONS
1	Key summary of German national treatment guidance for hospitalized COVID-19 patients. <i>Infection</i> , 2022, 50, 93-106.	2.3	30
2	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-“Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 275-287.	2.5	72
3	Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation. <i>European Respiratory Journal</i> , 2022, 59, 2100142.	3.1	10
4	Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma. <i>Chest</i> , 2022, 162, 46-55.	0.4	19
5	Longitudinal Impact of Sputum Inflammatory Phenotypes on Small Airway Dysfunction and Disease Outcomes in Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1545-1553.e2.	2.0	28
6	The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 661-668.	5.2	41
7	Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥ 500 cells/ μ L. <i>European Respiratory Journal</i> , 2022, 59, 2102577.	3.1	2
8	Relationship between prior inhaled corticosteroid use and benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study. <i>Respiratory Medicine</i> , 2022, 197, 106857.	1.3	3
9	Predictive modeling of COPD exacerbation rates using baseline risk factors. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211073.	1.0	10
10	Early-life exposure to tobacco smoke alters airway signaling pathways and later mortality in <i>D. melanogaster</i> . <i>Environmental Pollution</i> , 2022, 309, 119696.	3.7	1
11	Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study. <i>EClinicalMedicine</i> , 2022, 51, 101549.	3.2	66
12	RNA-seq-based profiling of extracellular vesicles in plasma reveals a potential role of miR-122 in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 366-371.	2.7	18
13	Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 735-750.	2.7	83
14	Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort. <i>European Respiratory Journal</i> , 2021, 57, 2002127.	3.1	8
15	Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 553-564.	2.5	134
16	Cytokine levels in children and adults with wheezing and asthma show specific patterns of variability over time. <i>Clinical and Experimental Immunology</i> , 2021, 204, 152-164.	1.1	5
17	Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials. <i>Advances in Therapy</i> , 2021, 38, 579-593.	1.3	10
18	DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer. <i>Clinical Epigenetics</i> , 2021, 13, 38.	1.8	8

#	ARTICLE	IF	CITATIONS
19	Sex dependent effect of maternal e-nicotine on F1 Drosophila development and airways. Scientific Reports, 2021, 11, 4441.	1.6	11
20	Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. European Respiratory Journal, 2021, 58, 2003393.	3.1	69
21	Influence of Cell Quality on Inflammatory Biomarkers in COPD Sputum Supernatant. International Journal of COPD, 2021, Volume 16, 487-493.	0.9	3
22	Persistent Uncontrolled Asthma: Long-Term Impact on Physical Activity and Body Composition. Journal of Asthma and Allergy, 2021, Volume 14, 229-240.	1.5	14
23	Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine, 2021, 9, 476-486.	5.2	254
24	Allergen extract- and component- based diagnostics in children of the ALLIANCE asthma cohort. Clinical and Experimental Allergy, 2021, 51, 1331-1345.	1.4	6
25	Raised sputum extracellular DNA confers lung function impairment and poor symptom control in an exacerbation-susceptible phenotype of neutrophilic asthma. Respiratory Research, 2021, 22, 167.	1.4	10
26	COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy. European Respiratory Journal, 2021, 58, 2003969.	3.1	15
27	Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respiratory Medicine, 2021, 9, 1288-1298.	5.2	75
28	The Relevance of Small Airway Dysfunction in Asthma with Nocturnal Symptoms. Journal of Asthma and Allergy, 2021, Volume 14, 897-905.	1.5	17
29	Lung function fluctuation patterns unveil asthma and COPD phenotypes unrelated to type 2 inflammation. Journal of Allergy and Clinical Immunology, 2021, 148, 407-419.	1.5	16
30	Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. Respiratory Medicine, 2021, 185, 106509.	1.3	12
31	Small Airway Dysfunction Links Asthma Severity with Physical Activity and Symptom Control. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3359-3368.e1.	2.0	39
32	Recommendations on Inpatient Treatment of Patients With COVID-19. Deutsches Ärztblatt International, 2021, 118, .	0.6	35
33	Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler <i>versus</i> dual therapies in patients with COPD: a sub-study of the ETHOS trial. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662110343.	1.0	11
34	Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. New England Journal of Medicine, 2021, 385, 1656-1668.	13.9	183
35	Impact of imposed social isolation and use of face masks on asthma course and mental health in pediatric and adult patients with recurrent wheeze and asthma. Allergy, Asthma and Clinical Immunology, 2021, 17, 93.	0.9	3
36	Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 527-539.e9.	2.0	45

#	ARTICLE	IF	CITATIONS
37	Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 261-271.	1.4	15
38	The effect of dupilumab on lung function parameters in patients with oral corticosteroid-dependent severe asthma. <i>Respiratory Medicine: X</i> , 2020, 2, 100010.	1.4	3
39	High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study. <i>European Respiratory Journal</i> , 2020, 55, 1901314.	3.1	26
40	Triple Inhaled Therapy in COPD. <i>New England Journal of Medicine</i> , 2020, 383, 1393-1395.	13.9	1
41	Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study. <i>Respiratory Research</i> , 2020, 21, 278.	1.4	25
42	Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. <i>Respiratory Research</i> , 2020, 21, 177.	1.4	13
43	Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19. <i>Immunity</i> , 2020, 53, 1296-1314.e9.	6.6	278
44	Exploration of the sputum methylome and omics deconvolution by quadratic programming in molecular profiling of asthma and COPD: the road to sputum omics 2.0. <i>Respiratory Research</i> , 2020, 21, 274.	1.4	6
45	Benefits of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) on Symptoms and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease (COPD) in the ETHOS Trial. , 2020, , .		0
46	DUPILUMAB IMPROVES LUNG FUNCTION IN PATIENTS IRRESPECTIVE OF ON-STUDY ASTHMA EXACERBATIONS. <i>Chest</i> , 2020, 158, A1729-A1733.	0.4	0
47	BENEFITS OF BUDESONIDE-CONTAINING THERAPIES ON REDUCING LUNG FUNCTION DECLINE IN PATIENTS WITH COPD IN THE ETHOS STUDY. <i>Chest</i> , 2020, 158, A1656-A1659.	0.4	2
48	Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. <i>Clinical and Translational Allergy</i> , 2020, 10, 58.	1.4	56
49	Single-Inhaler Triple Combination Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) at Two Corticosteroid Dose Levels in COPD: ETHOS Trial. , 2020, , .		0
50	Improvements in Lung Function with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Dual Therapies in Patients with COPD: A Sub-Study of the ETHOS Trial. , 2020, , .		1
51	COL4A3 Degradation Is Increased in Severe, Type 2 Exacerbating Asthmatics. , 2020, , .		0
52	COL4A3 Degradation Predicts Anti-IgE Treatment Response in Severe Asthma. , 2020, , .		0
53	SAR440340, An Anti-IL-33 Monoclonal Antibody, Demonstrated a Significant Reduction of LOAC Events and Improved Pre-BD FEV1 in Patients with Moderate to Severe Asthma: Results from the Phase 2 Proof of Concept Study. , 2020, , .		2
54	Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies. <i>Respiratory Research</i> , 2020, 21, 128.	1.4	4

#	ARTICLE	IF	CITATIONS
55	Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. <i>New England Journal of Medicine</i> , 2020, 383, 35-48.	13.9	329
56	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. <i>Clinical and Translational Allergy</i> , 2020, 10, 16.	1.4	97
57	Dupilumab Reduces Oral Corticosteroid Use and Severe Exacerbations and Improves Lung Function in Patients With Oral Corticosteroid-Dependent Severe Asthma With and Without Comorbid Allergic Rhinitis in the Phase 3 LIBERTY ASTHMA VENTURE Study. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, AB173.	1.5	1
58	Dupilumab Efficacy in GINA-Defined Difficult-to-Treat Type 2 Asthma Patients. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, AB19.	1.5	0
59	Benefits of Tiotropium/Olodaterol Over Tiotropium Alone in Delaying Clinically Significant Deterioration in Patients with COPD. , 2020, , .		0
60	Correlation between work impairment, scores of rhinitis severity and asthma using the MASK ^{air} App. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1672-1688.	2.7	32
61	Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies. <i>International Journal of COPD</i> , 2020, Volume 15, 99-106.	0.9	3
62	Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. <i>ERJ Open Research</i> , 2020, 6, 00204-2019.	1.1	36
63	Longitudinal data-driven definition of clinical asthma phenotypes in the pediatric arm of the All Age Asthma Cohort (ALLIANCE) of the German Center for Lung Research (DZL). , 2020, , .		1
64	The role of eosinophils in pediatric and adult asthma. , 2020, , .		1
65	Allergen-Immuntherapie in der aktuellen COVID-19-Pandemie – ein Positionspapier von ARIA, EAACI, AeDA und DGAKI. <i>Allergologie</i> , 2020, 43, 165-175.	0.1	2
66	Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie – ein Positionspapier von AeDA, DGAKI, GPA, A-GAI, LGAI, A-GP, ARIA und EAACI. <i>Allergologie</i> , 2020, 43, 255-271.	0.1	9
67	Beitrag der intraoperativen Zytologie zur Schnell-Diagnostik thoraxchirurgisch gewonnener Proben. <i>Pneumologie</i> , 2020, 74, .	0.1	0
68	12-Hour Lung Function Assessment of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Delivered by Co-suspension Delivery Technology in Patients with COPD. , 2020, 74, .		0
69	Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis. , 2020, , .		1
70	Iron deficiency and lung function decline in stable COPD – a prospective cohort study. , 2020, , .		0
71	Small airway evolution of a Brazilian severe asthmatic cohort (BRASASP): 10 years follow up. , 2020, , .		0
72	Asthmaphänotypen in der ALL Age Asthma Kohorte – ALLIANCE – des DZL – Aktueller Stand, Ergebnisse, Ausblick. <i>Pneumologie</i> , 2020, 74, .	0.1	0

#	ARTICLE	IF	CITATIONS
73	Seasonal Variation in COPD Exacerbations: a Post-Hoc Analysis from the KRONOS Phase III Study of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI). <i>Pneumologie</i> , 2020, 74, .	0.1	0
74	COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels. , 2020, , .		0
75	Predictive modelling of COPD exacerbation rates using baseline risk factors. , 2020, , .		0
76	Late Breaking Abstract - COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS. , 2020, , .		0
77	Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial. , 2020, , .		0
78	The pro-resolving lipid mediator lipoxin A4 inversely correlates with proinflammatory chemokines and identifies a subgroup of asthma patients with disease progression. , 2020, , .		0
79	Effect of dupilumab on severe exacerbations and lung function in patients with baseline blood eosinophils ≥ 500 cells/ μ L. , 2020, , .		0
80	Late Breaking Abstract - Small Airways Dysfunction (SAD) correlates with relevant asthma outcomes: longitudinal results from the Assessment of small Airways involvement In asthma (ATLANTIS) Study. , 2020, , .		1
81	Malignes Mesotheliom: Vor- und Nachteile der zytologischen Untersuchung von ErgÄ½ssen. <i>Atemwegs- Und Lungenkrankheiten</i> , 2020, 46, 651-657.	0.0	0
82	Treatment of First Exacerbation Predicts Future Risk of Exacerbations in Patients with COPD in the DYNAGITO Trial. , 2019, , .		0
83	COPD EXACERBATION RATE BY BASELINE COPD ASSESSMENT TEST SCORE IN THE DYNAGITO STUDY. <i>Chest</i> , 2019, 156, A1758-A1759.	0.4	0
84	A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6â€¹¼g and 160/18/9.6â€¹¼g using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. <i>Respiratory Medicine</i> , 2019, 158, 59-66.		27
85	Dupilumab Improved Lung Function in Patients with Uncontrolled, Moderate-to-Severe Asthma. , 2019, , .		0
86	The Fevipiprant Phase IIIb Systemic Corticosteroid Avoidance Study: SHIELD. , 2019, , .		0
87	Rating sputum cell quality in clinical trials for asthma and COPD treatment. <i>International Journal of COPD</i> , 2019, Volume 14, 195-198.	0.9	6
88	Dupilumab Improved Asthma Control and Health-Related Quality of Life in Patients with Oral-Corticosteroid-Dependent Severe Asthma in the Phase 3 LIBERTY ASTHMA VENTURE Study. , 2019, , .		0
89	Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. <i>Clinical and Translational Allergy</i> , 2019, 9, 16.	1.4	81
90	Cryobiopsy for Interstitial Lung Disease: The Heat Is On. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1183-1184.	2.5	12

#	ARTICLE	IF	CITATIONS
91	Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 56, 86-93.	1.1	41
92	Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 402-416.	5.2	225
93	Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD. <i>Respiratory Research</i> , 2019, 20, 61.	1.4	11
94	Dupilumab Reduces Severe Exacerbations and Improves Lung Function Regardless of Baseline Bronchodilator Reversibility in Patients with Uncontrolled Moderate-to-Severe Asthma Enrolled in the LIBERTY ASTHMA QUEST Study. , 2019, , .		0
95	Dupilumab Improved Lung Function in Patients with Uncontrolled, Moderate-to-Severe Asthma Despite Exacerbation Events During the LIBERTY ASTHMA QUEST Study. , 2019, , .		0
96	Dupilumab Improved Morning and Evening Daily Asthma Symptoms in Patients with Oral-Corticosteroid-Dependent Severe Asthma in the Phase 3 LIBERTY ASTHMA VENTURE Study. , 2019, , .		0
97	Seasonal Pattern of COPD Exacerbations in the DYNAGITO Trial. , 2019, , .		1
98	Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Improves Lung Function in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies. , 2019, , .		1
99	12-Hour Lung Function Assessment of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Delivered by Co-Suspension Delivery Technology in Patients with COPD. , 2019, , .		0
100	The Frequency of Exacerbations Treated with Antibiotics, Steroids or Both Differs by GOLD Stage in Patients with COPD in the DYNAGITO Trial. , 2019, , .		0
101	<p>Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2993-3002.	0.9	12
102	Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancy. <i>Clinical Epigenetics</i> , 2019, 11, 157.	1.8	16
103	<p>Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2979-2991.	0.9	12
104	Adherence to treatment in allergic rhinitis using mobile technology. The <sc>MASK</sc> Study. <i>Clinical and Experimental Allergy</i> , 2019, 49, 442-460.	1.4	73
105	New Biologics for Severe Asthma: What Patients, What Agents, What Results, at What Cost?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 406-408.	2.5	5
106	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 46-59.	5.2	216
107	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 864-879.	1.5	103
108	Economic burden of bronchiectasis in Germany. <i>European Respiratory Journal</i> , 2019, 53, 1802033.	3.1	44

#	ARTICLE	IF	CITATIONS
109	The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC. <i>Frontiers in Oncology</i> , 2019, 9, 1550.	1.3	26
110	Eosinophil counts as a predictor of future COPD exacerbations in the DYNAGITO trial. , 2019, , .		1
111	Dupilumab Efficacy in Type 2 Inflammatory Asthma: Liberty Asthma QUEST Study. , 2019, , .		2
112	Late Breaking Abstract - Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF). , 2019, , .		10
113	Extrapulmonary effects of COPD. , 2019, , 339-343.		0
114	Pneumonia risk with budesonide-containing therapies in COPD: pooled analysis of three Phase III studies. , 2019, , .		0
115	Regional analysis of COPD exacerbation rates in the DYNAGITO trial. , 2019, , .		0
116	Analysis of exacerbation rates by time interval post-randomization in the KRONOS Phase III study of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI). , 2019, , .		0
117	Late Breaking Abstract - Blood eosinophil count and exacerbation history in COPD: pooled analysis of 24,103 patients. , 2019, , .		0
118	Breath volatile organic compound (VOC) patterns in adult asthma patients of the ALLIANCE cohort. , 2019, , .		2
119	miR-122-5p and miR-191-5p are increased in plasma small extracellular vesicles in asthma. , 2019, , .		1
120	S29â€¦The impact of GOLD stage on the effectiveness of tiotropium/olodaterol in preventing COPD exacerbations in the DYNAGITO trial. , 2019, , .		0
121	S102â€¦Eosinophil counts as a predictor of future COPD exacerbations in the DYNAGITO trial. , 2019, , .		0
122	Neutrophil extracellular trap formation is regulated by CXCR2 in COPD neutrophils. <i>European Respiratory Journal</i> , 2018, 51, 1700970.	3.1	49
123	Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 337-344.	5.2	149
124	Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease. <i>Chest</i> , 2018, 153, 888-921.	0.4	102
125	Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?. <i>European Respiratory Journal</i> , 2018, 51, 1702577.	3.1	4
126	Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. <i>Advances in Therapy</i> , 2018, 35, 737-748.	1.3	129

#	ARTICLE	IF	CITATIONS
127	Airway pathology in severe asthma is related to airflow obstruction but not symptom control. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 635-643.	2.7	30
128	Physical Activity and Fatigue in Patients with Sarcoidosis. <i>Respiration</i> , 2018, 95, 18-26.	1.2	22
129	Rhinovirus infections change DNA methylation and mRNA expression in children with asthma. <i>PLoS ONE</i> , 2018, 13, e0205275.	1.1	39
130	Cardiovascular disease and COPD: dangerous liaisons?. <i>European Respiratory Review</i> , 2018, 27, 180057.	3.0	187
131	MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. <i>Clinical and Translational Allergy</i> , 2018, 8, 45.	1.4	104
132	Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 747-758.	5.2	254
133	Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 827-836.	5.2	46
134	Inhaled corticosteroids in COPD: friend or foe?. <i>European Respiratory Journal</i> , 2018, 52, 1801219.	3.1	166
135	Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 813-822.	0.9	21
136	Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1268-1278.	2.5	60
137	Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 2486-2496.	13.9	1,253
138	Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 2475-2485.	13.9	816
139	Combined Analysis of Asthma Safety Trials of Long-Acting β_2 -Agonists. <i>New England Journal of Medicine</i> , 2018, 378, 2497-2505.	13.9	76
140	Human alveolar epithelial cells type II are capable of TGF β ² -dependent epithelial-mesenchymal-transition and collagen-synthesis. <i>Respiratory Research</i> , 2018, 19, 138.	1.4	52
141	Fountain of youth for squamous cell carcinomas? On the epigenetic age of non-small cell lung cancer and corresponding tumor-free lung tissues. <i>International Journal of Cancer</i> , 2018, 143, 3061-3070.	2.3	8
142	Influence of body mass on predicted values of static hyperinflation in COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 2551-2555.	0.9	5
143	The all age asthma cohort (ALLIANCE) - from early beginnings to chronic disease: a longitudinal cohort study. <i>BMC Pulmonary Medicine</i> , 2018, 18, 140.	0.8	44
144	Identification of novel target genes in human lung tissue involved in chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2018, Volume 13, 2255-2259.	0.9	16

#	ARTICLE	IF	CITATIONS
145	Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST. , 2018, , .		5
146	KRONOS: 24-week study of triple fixed-dose combination budesonide/glycopyrronium/formoterol (BGF) MDI via co-suspension delivery technology vs glycopyrronium/formoterol (GFF) MDI, budesonide/formoterol (BFF) MDI and BFF inhalation powder in COPD. , 2018, , .		1
147	Late Breaking Abstract - High-sensitivity troponin I predicts all-cause mortality in stable COPD in the COSYCONET cohort. , 2018, , .		2
148	Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in corticosteroid (CS)-dependent severe asthma patients in LIBERTY ASTHMA VENTURE. , 2018, , .		2
149	Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF) Tj ETQq1 1 0.784314 µgBT /Over		
150	Beitrag der Zytologie zur Diagnostik von Thymustumoren. Atemwegs- Und Lungenkrankheiten, 2018, 44, 383-389.	0.0	0
151	Influences of obstruction and hyperinflation on electrocardiographic P wave, QRS and T wave axis in COPD. , 2018, , .		0
152	Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in asthma patients in LIBERTY ASTHMA QUEST. , 2018, , .		1
153	Influence of body mass on predicted values of static hyperinflation in COPD. , 2018, , .		0
154	A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension [®] , [®] Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. Respiratory Research, 2017, 18, 8.	1.4	21
155	FEV1 and FVC predict all-cause mortality independent of cardiac function “ Results from the population-based Gutenberg Health Study. International Journal of Cardiology, 2017, 234, 64-68.	0.8	40
156	Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium. Pulmonary Pharmacology and Therapeutics, 2017, 45, 19-33.	1.1	20
157	Burden of non-tuberculous mycobacterial pulmonary disease in Germany. European Respiratory Journal, 2017, 49, 1602109.	3.1	100
158	Chronic obstructive pulmonary disease. Lancet, The, 2017, 389, 1931-1940.	6.3	712
159	Severe eosinophilic asthma: a roadmap to consensus. European Respiratory Journal, 2017, 49, 1700634.	3.1	143
160	GFF MDI for the improvement of lung function in COPD “ A look at the PINNACLE-1 and PINNACLE-2 data and beyond. Expert Review of Clinical Pharmacology, 2017, 10, 685-698.	1.3	4
161	Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. Chest, 2017, 151, 340-357.	0.4	91
162	Oral Glucocorticoid “Sparing Effect of Benralizumab in Severe Asthma. New England Journal of Medicine, 2017, 376, 2448-2458.	13.9	779

#	ARTICLE	IF	CITATIONS
163	Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 45, 121-123.	1.1	47
164	Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017, 49, 1600791.	3.1	438
165	Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A <sc>EUFOREA</sc> – <sc>ARIA</sc> – <sc>EPOS</sc> – <sc>AIRWAYS ICP</sc> statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1297-1305.	2.7	130
166	Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids. <i>European Respiratory Journal</i> , 2017, 49, 1600839.	3.1	22
167	Physical activity, airway resistance and small airway dysfunction in severe asthma. <i>European Respiratory Journal</i> , 2017, 49, 1601827.	3.1	44
168	Precision Diagnosis and Treatment for Advanced Non-“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 849-861.	13.9	578
169	Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017, 50, 1602265.	3.1	131
170	Lipidomes of lung cancer and tumour-free lung tissues reveal distinct molecular signatures for cancer differentiation, age, inflammation, and pulmonary emphysema. <i>Scientific Reports</i> , 2017, 7, 11087.	1.6	36
171	Advanced Non-“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 1997-1999.	13.9	17
172	Esophageal ultrasound (EUS) assessment of T4 status in NSCLC patients. <i>Lung Cancer</i> , 2017, 114, 50-55.	0.9	5
173	Effect of roflumilast in patients with severe COPD and a history of hospitalisation. <i>European Respiratory Journal</i> , 2017, 50, 1700158.	3.1	39
174	Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: a brief history of time. <i>European Respiratory Journal</i> , 2017, 50, 1700671.	3.1	69
175	Asthma transition from childhood into adulthood. <i>Lancet Respiratory Medicine</i> , 2017, 5, 224-234.	5.2	165
176	Peripheral eosinophil count as a biomarker for the management of COPD: not there yet. <i>European Respiratory Journal</i> , 2017, 50, 1702165.	3.1	15
177	Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis. <i>BMC Pulmonary Medicine</i> , 2017, 17, 104.	0.8	51
178	Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. <i>BMC Pulmonary Medicine</i> , 2017, 17, 122.	0.8	94
179	Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function. <i>International Journal of COPD</i> , 2017, Volume 12, 981-987.	0.9	26
180	Reduced microRNA-503 expression augments lung fibroblast VEGF production in chronic obstructive pulmonary disease. <i>PLoS ONE</i> , 2017, 12, e0184039.	1.1	16

#	ARTICLE	IF	CITATIONS
181	Molecular phenotyping of chronic bronchitis: mucin and inflammatory gene expression heterogeneity in COPD. , 2017, , .		0
182	Blood eosinophil (EOS) count, exacerbation rate and response to roflumilast in patients with severe COPD. , 2017, , .		0
183	Physical activity in patients with sarcoidosis. , 2017, , .		0
184	Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β_2 -agonist fixed-dose combination: Rationale and study design. International Journal of COPD, 2016, Volume 11, 1921-1928.	0.9	9
185	Roflumilast: a review of its use in the treatment of COPD. International Journal of COPD, 2016, 11, 81.	0.9	119
186	Exacerbations of COPD. International Journal of COPD, 2016, 11 Spec Iss, 21.	0.9	79
187	Reduced physical activity in lymphangiomyomatosis compared with COPD and healthy controls: disease-specific impact and clinical correlates. Thorax, 2016, 71, 662-663.	2.7	6
188	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 2016, 6, 47.	1.4	121
189	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	1.5	128
190	Endoscopic Lung Volume Reduction: An Expert Panel Recommendation. Respiration, 2016, 91, 241-250.	1.2	48
191	AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. European Respiratory Journal, 2016, 47, 1028-1033.	3.1	50
192	The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respiratory Medicine, 2016, 114, 27-37.	1.3	113
193	Update in Asthma 2015. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 259-264.	2.5	4
194	Clinical Correlates of Reduced Physical Activity in Idiopathic Pulmonary Fibrosis. Respiration, 2016, 91, 497-502.	1.2	61
195	Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β_2 -Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RESPIRON). A Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 559-567.	2.5	109
196	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 2016, 6, 29.	1.4	47
197	Can severe asthmatic patients achieve asthma control? A systematic approach in patients with difficult to control asthma followed in a specialized clinic. BMC Pulmonary Medicine, 2016, 16, 153.	0.8	15
198	Lung Function Abnormalities in Smokers with Ischemic Heart Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 568-576.	2.5	53

#	ARTICLE	IF	CITATIONS
199	Angiotensin-like protein 4 and cardiovascular function in COPD. <i>BMJ Open Respiratory Research</i> , 2016, 3, e000161.	1.2	10
200	P294 Benefits of tiotropium/olodaterol over tiotropium at delaying clinically significant events in patients with COPD classified as GOLD B. <i>Thorax</i> , 2016, 71, A251.3-A252.	2.7	0
201	Downregulation of the TGF β 2 Pseudoreceptor BAMBI in Non-Small Cell Lung Cancer Enhances TGF β 2 Signaling and Invasion. <i>Cancer Research</i> , 2016, 76, 3785-3801.	0.4	75
202	Subclinical impairment of lung function is related to mild cardiac dysfunction and manifest heart failure in the general population. <i>International Journal of Cardiology</i> , 2016, 218, 298-304.	0.8	43
203	Screening for <i>Helicobacter pylori</i> in Idiopathic Pulmonary Fibrosis Lung Biopsies. <i>Respiration</i> , 2016, 91, 3-8.	1.2	20
204	Assessing small airway impairment in mild-to-moderate smoking asthmatic patients. <i>European Respiratory Journal</i> , 2016, 47, 1264-1267.	3.1	11
205	The use of auto-antibody testing in the evaluation of interstitial lung disease (ILD) – A practical approach for the pulmonologist. <i>Respiratory Medicine</i> , 2016, 113, 80-92.	1.3	29
206	Increased YKL-40 and Chitotriosidase in Asthma and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 131-142.	2.5	107
207	Beneficial effect of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) fixed-dose combination, delivered using a novel MDI co-suspension technology (GFF MDI), in COPD GOLD group A and B patients. , 2016, , .		1
208	Safety and tolerability of the NE inhibitor BAY 85-8501 in patients with non-CF bronchiectasis. , 2016, , .		4
209	Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE). , 2016, , .		0
210	Physical activity in patients with asthma. , 2016, , .		0
211	Long-acting bronchodilators (LABDs) and major adverse cardiac events (MACE) in patients with COPD: A pooled analysis of 12 randomised trials. , 2016, , .		0
212	International perspectives on severe asthma: Current and future challenges in patient care. , 2016, , .		0
213	Neutrophils in bronchial mucosa, sputum and blood after administration of the CXCR2-antagonist AZD5069 - An explorative study in neutrophilic asthma. , 2016, , .		0
214	Association of angiotensin-like protein 4 with cardiovascular function in patients with COPD. , 2016, , .		0
215	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1372-1392.	2.7	160
216	Elastic Recoil Revisited. <i>Chest</i> , 2015, 148, 297-298.	0.4	0

#	ARTICLE	IF	CITATIONS
217	Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?. <i>Diagnostic Pathology</i> , 2015, 10, 130.	0.9	70
218	Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2015, 10, 549.	0.9	26
219	Nasal Levels of Antimicrobial Peptides in Allergic Asthma Patients and Healthy Controls: Differences and Effect of a Short 1,25(OH) ₂ Vitamin D ₃ Treatment. <i>PLoS ONE</i> , 2015, 10, e0140986.	1.1	18
220	Disease Progression and Changes in Physical Activity in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 295-306.	2.5	195
221	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Review</i> , 2015, 24, 159-172.	3.0	72
222	Increased expression of granzymes A and B in fatal asthma. <i>European Respiratory Journal</i> , 2015, 45, 1485-1488.	3.1	16
223	Overweight can be used as a tool to guide case-finding for cardiovascular risk assessment. <i>Family Practice</i> , 2015, 32, 646-651.	0.8	1
224	Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. <i>Lancet</i> , The, 2015, 385, 857-866.	6.3	309
225	Multi-analyte profiling of inflammatory mediators in COPD sputum – The effects of processing. <i>Cytokine</i> , 2015, 71, 401-404.	1.4	20
226	Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma. <i>European Respiratory Journal</i> , 2015, 45, 1273-1282.	3.1	22
227	Bronchopulmonary lymph nodes and large airway cell trafficking in patients with fatal asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1352-1357.e9.	1.5	17
228	Lung cancer staging: a true story. <i>Lancet Respiratory Medicine</i> , the, 2015, 3, 258-259.	5.2	4
229	Treatment of COPD and the TONado trial: a tempest in a teapot?. <i>European Respiratory Journal</i> , 2015, 45, 869-871.	3.1	5
230	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, e4-e27.	2.5	166
231	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015, 45, 879-905.	3.1	138
232	The Aging Lung: Clinical and Imaging Findings and the Fringe of Physiological State. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2015, 187, 430-439.	0.7	7
233	Emphysema: Imaging for Endoscopic Lung Volume Reduction. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2015, 187, 543-554.	0.7	5
234	The Asthma – COPD Overlap Syndrome. <i>New England Journal of Medicine</i> , 2015, 373, 1241-1249.	13.9	489

#	ARTICLE	IF	CITATIONS
235	Roflumilast for asthma: Efficacy findings in mechanism of action studies. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 35, S4-S10.	1.1	43
236	Neutrophil extracellular trap formation and extracellular DNA in sputum of stable COPD patients. <i>Respiratory Medicine</i> , 2015, 109, 1360-1362.	1.3	62
237	Roflumilast for asthma: Weighing the evidence. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 35, S1-S3.	1.1	4
238	Unmet needs for the assessment of small airways dysfunction in asthma: introduction to the ATLANTIS study. <i>European Respiratory Journal</i> , 2015, 45, 1534-1538.	3.1	23
239	Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy. , 2015, , .		1
240	Enhanced neutrophil extracellular trap (NET) formation in sputum of stable COPD patients. , 2015, , .		2
241	LATE-BREAKING ABSTRACT: PT003, a novel co-suspension MDI glycopyrronium/formoterol fixed-dose combination is superior to monocomponents in patients with COPD. , 2015, , .		1
242	Association of Lung Inflammatory Cells with Small Airways Function and Exhaled Breath Markers in Smokers – Is There a Specific Role for Mast Cells?. <i>PLoS ONE</i> , 2015, 10, e0129426.	1.1	4
243	Versican and collagen-III expression in bronchial and pulmonary muscular arteries in COPD patients. , 2015, , .		0
244	The role of sustained physical inactivity in the progression of exercise intolerance and muscle depletion in COPD. , 2015, , .		0
245	Reproducibility of exhaled nitric oxide measurements in overweight and obese adults. <i>BMC Research Notes</i> , 2014, 7, 775.	0.6	4
246	Reprogramming of COPD lung fibroblasts through formation of induced pluripotent stem cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014, 306, L552-L565.	1.3	13
247	The European Respiratory Society plans its future: the 2013-2018 strategic plan. <i>European Respiratory Journal</i> , 2014, 43, 927-932.	3.1	15
248	Asthma in the elderly: what we know and what we have yet to know. <i>World Allergy Organization Journal</i> , 2014, 7, 8.	1.6	105
249	Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 44-53.	5.2	44
250	Frequent exacerbators – a distinct phenotype of severe asthma. <i>Clinical and Experimental Allergy</i> , 2014, 44, 212-221.	1.4	132
251	Implementing lessons learned from previous bronchial biopsy trials in a new randomized controlled COPD biopsy trial with roflumilast. <i>BMC Pulmonary Medicine</i> , 2014, 14, 9.	0.8	12
252	Chronic obstructive pulmonary disease and exacerbations: clinician insights from the global Hidden Depths of COPD survey. <i>Current Medical Research and Opinion</i> , 2014, 30, 667-684.	0.9	13

#	ARTICLE	IF	CITATIONS
253	New metrics for translational research. <i>Lancet Respiratory Medicine</i> , 2014, 2, e13-e14.	5.2	4
254	Respiratory diseases in the world: one voice "united for lung health". <i>European Respiratory Journal</i> , 2014, 43, 3-5.	3.1	9
255	Association of lung function measurements and visceral fat in men with metabolic syndrome. <i>Respiratory Medicine</i> , 2014, 108, 351-357.	1.3	30
256	Integrated care pathways for airway diseases (AIRWAYS-ICPs). <i>European Respiratory Journal</i> , 2014, 44, 304-323.	3.1	154
257	Point: Were Industry-Sponsored Roflumilast Trials Appropriate? Yes. <i>Chest</i> , 2014, 145, 937-939.	0.4	6
258	Response. <i>Chest</i> , 2014, 145, 428.	0.4	1
259	Rebuttal From Drs Suissa and Rabe. <i>Chest</i> , 2014, 145, 942-943.	0.4	0
260	Management of non-small-cell lung cancer: recent developments. <i>Lancet, The</i> , 2013, 382, 709-719.	6.3	658
261	An Official American Thoracic Society/European Respiratory Society Policy Statement: Disparities in Respiratory Health. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 865-871.	2.5	72
262	Chronic obstructive pulmonary disease and exacerbations: Patient insights from the global Hidden Depths of COPD survey. <i>BMC Pulmonary Medicine</i> , 2013, 13, 54.	0.8	58
263	Immune cell profile in infants' lung tissue. <i>Annals of Anatomy</i> , 2013, 195, 596-604.	1.0	11
264	HOPE-preservation of paraffin-embedded sputum samples – A new way of bioprofiling in COPD. <i>Respiratory Medicine</i> , 2013, 107, 587-595.	1.3	13
265	Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2013, 1, 23-31.	5.2	125
266	Phosphodiesterase-4 Inhibitor Therapy for Lung Diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 271-278.	2.5	90
267	CD8+ T cells characterize early smoking-related airway pathology in patients with asthma. <i>Respiratory Medicine</i> , 2013, 107, 959-966.	1.3	23
268	Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients. <i>Respiratory Medicine</i> , 2013, 107, 75-83.	1.3	20
269	Global Initiative on Obstructive Lung Disease Revised. What Constitutes a Guideline?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1035-1036.	2.5	9
270	An Official American Thoracic Society/European Respiratory Society Statement: The Role of the Pulmonologist in the Diagnosis and Management of Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 503-507.	2.5	54

#	ARTICLE	IF	CITATIONS
271	Endosonography vs Conventional Bronchoscopy for the Diagnosis of Sarcoidosis. JAMA - Journal of the American Medical Association, 2013, 309, 2457.	3.8	209
272	Pulmonologists and lung cancer: pivotal role in multidisciplinary approach. European Respiratory Journal, 2013, 42, 1183-1185.	3.1	10
273	Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respiratory Research, 2013, 14, 116.	1.4	65
274	An official American Thoracic Society and European Respiratory Society policy statement: disparities in respiratory health. European Respiratory Journal, 2013, 42, 906-915.	3.1	18
275	The Effect of Dithiothreitol on the Transcriptome of Induced Sputum Cells. Respiration, 2013, 86, 262-263.	1.2	4
276	Efficacy of Roflumilast in the COPD Frequent Exacerbator Phenotype. Chest, 2013, 143, 1302-1311.	0.4	106
277	Cardiovascular Safety in Patients Receiving Roflumilast for the Treatment of COPD. Chest, 2013, 144, 758-765.	0.4	95
278	Seasonal Distribution of COPD Exacerbations in the Prevention of Exacerbations With Tiotropium in COPD Trial. Chest, 2013, 143, 711-719.	0.4	63
279	Anti-inflammatory effects of budesonide in human lung fibroblasts are independent of histone deacetylase 2. Journal of Inflammation Research, 2013, 6, 109.	1.6	10
280	Extrapulmonary effects of COPD. , 2013, , 300-303.		0
281	The EvA study: aims and strategy. European Respiratory Journal, 2012, 40, 823-829.	3.1	29
282	The race for healthy lungs starts with spirometry testing. Breathe, 2012, 8, 273-275.	0.6	0
283	World Spirometry Day 2012: the highlights so far. Breathe, 2012, 9, 5-8.	0.6	1
284	Towards a total ban on links with the tobacco industry: new rules for the ERS. European Respiratory Journal, 2012, 40, 809-810.	3.1	6
285	Reporting and Publishing Guidelines. Proceedings of the American Thoracic Society, 2012, 9, 293-297.	3.5	13
286	How to Integrate Multiple Comorbidities in Guideline Development. Proceedings of the American Thoracic Society, 2012, 9, 274-281.	3.5	57
287	Effect of the Phosphodiesterase 4 Inhibitor Roflumilast on Glucose Metabolism in Patients with Treatment-Naive, Newly Diagnosed Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1720-E1725.	1.8	96
288	Extracellular matrix composition in COPD. European Respiratory Journal, 2012, 40, 1362-1373.	3.1	110

#	ARTICLE	IF	CITATIONS
289	Attenuation of Inhibitory Prostaglandin E2 Signaling in Human Lung Fibroblasts Is Mediated by Phosphodiesterase 4. American Journal of Respiratory Cell and Molecular Biology, 2012, 47, 729-737.	1.4	9
290	A Guide to Guidelines for Professional Societies and Other Developers of Recommendations. Proceedings of the American Thoracic Society, 2012, 9, 215-218.	3.5	29
291	Prof. Andrzej Szczeklik, 1938â€“2012: aspirin-induced asthma and much more: Figure 1â€“. European Respiratory Journal, 2012, 39, 1283-1286.	3.1	0
292	Avoiding backward steps in COPD: looking again at roflumilast. European Respiratory Journal, 2012, 39, 225-226.	3.1	0
293	Generation Of IPS-Like Cells From COPD Lung Fibroblasts. , 2012, , .		0
294	Drug Safety in COPD Revisited. Chest, 2012, 142, 271-274.	0.4	10
295	A Interdisciplinary Lung Transplant Center: A Collaboration Between a University Hospital and a Transregional Center for Pulmonology. Transplantation, 2012, 94, 935.	0.5	0
296	Uncovering and tackling Europe's hidden respiratory illness. Lancet, The, 2012, 380, 623-624.	6.3	7
297	Clinical characteristics and possible phenotypes of an adult severe asthma population. Respiratory Medicine, 2012, 106, 47-56.	1.3	57
298	Antiinflammatory Drugs. , 2012, , 213-220.		0
299	The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy. Respiratory Research, 2012, 13, 59.	1.4	37
300	Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. Journal of Allergy and Clinical Immunology, 2012, 130, 1049-1062.	1.5	486
301	Severe Chronic Allergic (and Related) Diseases: A Uniform Approach â€“ A MeDALL â€“ GA<sup>2</sup><sup>2</sup>LEN â€“ ARIA Position Paper. International Archives of Allergy and Immunology, 2012, 158, 216-231.	0.9	83
302	Toll-Like Receptor (TLR2 and TLR4) Polymorphisms and Chronic Obstructive Pulmonary Disease. PLoS ONE, 2012, 7, e43124.	1.1	43
303	Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol. International Journal of COPD, 2012, 7, 375.	0.9	30
304	Do small airway abnormalities characterize asthma phenotypes? In search of proof. Clinical and Experimental Allergy, 2012, 42, 1150-1160.	1.4	51
305	Concerns About Exercise Are Related to Walk Test Results in Pulmonary Rehabilitation for Patients with COPD. International Journal of Behavioral Medicine, 2012, 19, 39-47.	0.8	30
306	Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Medicine, 2011, 3, 43.	3.6	181

#	ARTICLE	IF	CITATIONS
307	Roflumilast with long-acting β_2 -agonists for COPD: influence of exacerbation history. <i>European Respiratory Journal</i> , 2011, 38, 553-560.	3.1	117
308	Illness perceptions and quality of life in Japanese and Dutch patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2011, 72, 384-390.	0.9	46
309	EUS-FNA for the detection of left adrenal metastasis in patients with lung cancer. <i>Lung Cancer</i> , 2011, 73, 310-315.	0.9	61
310	Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD. <i>New England Journal of Medicine</i> , 2011, 364, 1093-1103.	13.9	603
311	Controversies in treatment of chronic obstructive pulmonary disease. <i>Lancet, The</i> , 2011, 378, 1038-1047.	6.3	59
312	Tiotropium Reduces Exacerbations Versus Salmeterol Irrespective Of Baseline ICS Treatment In The Poet-COPD; Study. , 2011, , .		0
313	Seasonal Distribution Of Exacerbations In The Poet-COPD; Study. , 2011, , .		0
314	Anti-inflammatory Effects Of Budesonide In Human Lung Fibroblasts Are Independent Of HDAC2. , 2011, , .		0
315	Glycoproteins In Large And Small Airways And In Lung Parenchyma Of COPD Patients. , 2011, , .		0
316	Cigarette Smoke Extract Affects Release Of IL-8 And SLPI In Differentiated Primary Bronchial Epithelial Cell Cultures (PBEC) From COPD Versus Controls. , 2011, , .		0
317	Inhaled Long-Acting β_2 -Agonists Versus Anticholinergics in Older Patients With Chronic Obstructive Pulmonary Disease. <i>Annals of Internal Medicine</i> , 2011, 155, 561.	2.0	0
318	Major Adverse Cardiovascular Events In Patients With Chronic Obstructive Pulmonary Disease: Analysis Of 14 Pooled Roflumilast Studies. , 2011, , .		1
319	Identification Of Single Nucleotide Polymorphisms In MicroRNA 146A. , 2011, , .		0
320	Transesophageal Ultrasound-Guided Fine-Needle Aspiration for the Mediastinal Restaging of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1510-1515.	0.5	36
321	Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 671-678.	2.7	135
322	Can anti-IgE therapy prevent airway remodeling in allergic asthma?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 1142-1151.	2.7	50
323	Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. <i>British Journal of Pharmacology</i> , 2011, 163, 53-67.	2.7	201
324	Surgical Technique of Lower Lobe Lung Transplantation. <i>Annals of Thoracic Surgery</i> , 2011, 92, e39-e42.	0.7	15

#	ARTICLE	IF	CITATIONS
325	Smoking status and anti-inflammatory macrophages in bronchoalveolar lavage and induced sputum in COPD. <i>Respiratory Research</i> , 2011, 12, 34.	1.4	71
326	IL-4 and IL-13 exposure during mucociliary differentiation of bronchial epithelial cells increases antimicrobial activity and expression of antimicrobial peptides. <i>Respiratory Research</i> , 2011, 12, 59.	1.4	36
327	2010: the Year of the Lung. <i>European Respiratory Journal</i> , 2011, 37, 1-2.	3.1	7
328	Palliative Care Concepts in Respiratory Disease. <i>Respiration</i> , 2011, 82, 483-491.	1.2	16
329	The Multiple Components of COPD. , 2011, , 1-20.		2
330	EUS and EBUS in Non-“Small Cell Lung Cancer. , 2011, , 45-58.		0
331	Systemic Manifestations of COPD. <i>Chest</i> , 2011, 139, 165-173.	0.4	193
332	Generation and evaluation of a monoclonal antibody, designated MADL, as a new specific marker for adenocarcinomas of the lung. <i>British Journal of Cancer</i> , 2011, 105, 673-681.	2.9	6
333	Controlled and uncontrolled allergic asthma in routine respiratory specialist care – a clinical – epidemiological study in Germany. <i>Current Medical Research and Opinion</i> , 2011, 27, 1835-1847.	0.9	15
334	Mediastinum. , 2011, , 115-139.		1
335	Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCR. <i>PLoS ONE</i> , 2011, 6, e17791.	1.1	166
336	Cost-Effectiveness of Internet-Based Self-Management Compared with Usual Care in Asthma. <i>PLoS ONE</i> , 2011, 6, e27108.	1.1	40
337	Forced Expiratory Volume In One Second % Predicted Is Associated With Abnormal Aerobic Capacity In Patients With Limited And Diffuse Systemic Sclerosis. , 2010, , .		0
338	The dynamics of illness perceptions: Testing assumptions of Leventhal's common – sense model in a pulmonary rehabilitation setting. <i>British Journal of Health Psychology</i> , 2010, 15, 887-903.	1.9	50
339	Weekly self-monitoring and treatment adjustment benefit patients with partly controlled and uncontrolled asthma: an analysis of the SMASHING study. <i>Respiratory Research</i> , 2010, 11, 74.	1.4	51
340	Predominance of left – sided deep vein thrombosis and body weight. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2083-2084.	1.9	33
341	High – affinity immunoglobulin E receptor expression is increased in large and small airways in fatal asthma. <i>Clinical and Experimental Allergy</i> , 2010, 40, 1473-1481.	1.4	18
342	The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 141-151.	2.7	149

#	ARTICLE	IF	CITATIONS
343	Development and implementation of guidelines in allergic rhinitis – an ARIA – GA ² LEN paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1212-1221.	2.7	85
344	Reproducibility Of Exhaled NO Measurements In Overweight Subjects. , 2010, , .		0
345	Lumican And Biglycan Expression In Lungs Of COPD Patients. , 2010, , .		0
346	Is There A Good Tool To Measure Asthma Control On Severe Asthma Patients ?. , 2010, , .		0
347	Brazilian Severe Asthma Characterization And Its Phenotypes. , 2010, , .		0
348	Increased Lung-to-finger Circulation Time In obstructive Sleep Apnea. , 2010, , .		0
349	Prioritised research agenda for prevention and control of chronic respiratory diseases. European Respiratory Journal, 2010, 36, 995-1001.	3.1	125
350	Transesophageal endoscopic ultrasound-guided fine-needle aspiration for the mediastinal staging of extrathoracic tumors: a new perspective. Annals of Oncology, 2010, 21, 1468-1471.	0.6	20
351	Roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2010, 4, 543-555.	1.0	21
352	Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of sarcoidosis. Endoscopy, 2010, 42, 213-217.	1.0	54
353	Anticholinergic Drugs for the Treatment of COPD Are Safe – Are They?. Chest, 2010, 137, 1-3.	0.4	25
354	Endosonography for Lung Cancer Staging. Chest, 2010, 138, 765-767.	0.4	27
355	S35 A randomised controlled trial comparing combined EBUS/EUS followed by surgical staging versus surgical staging alone in non-small cell lung cancer: the ASTER study. Thorax, 2010, 65, A18-A18.	2.7	0
356	Theophylline for Chronic Obstructive Pulmonary Disease – Time to Move On. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 868-869.	2.5	7
357	Mediastinal-esophageal fistulae after EUS-FNA of tuberculosis of the mediastinum. Gastrointestinal Endoscopy, 2010, 71, 210-212.	0.5	30
358	Implementation of endoscopic ultrasound for lung cancer staging. Gastrointestinal Endoscopy, 2010, 71, 64-70.e1.	0.5	43
359	EUS-FNA in the preoperative staging of non-small cell lung cancer. Lung Cancer, 2010, 69, 60-65.	0.9	27
360	Chronic Obstructive Pulmonary Disease Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 598-604.	2.5	898

#	ARTICLE	IF	CITATIONS
361	Mediastinoscopy vs Endosonography for Mediastinal Nodal Staging of Lung Cancer. JAMA - Journal of the American Medical Association, 2010, 304, 2245.	3.8	517
362	The Year of the Lung. Lancet, The, 2010, 376, 753-754.	6.3	7
363	Self-harm on either side of the pond. Lancet, The, 2010, 376, 1224.	6.3	2
364	A randomized trial comparing endosonography followed by surgical staging versus surgical mediastinal staging alone in non-small cell lung cancer: The ASTER study.. Journal of Clinical Oncology, 2010, 28, 7000-7000.	0.8	3
365	Elastic Fiber Density in Large and Small Airways and Parenchyma in Lungs of Non-Smokers, Smokers and COPD Patients.. , 2009, , .		0
366	Muscarinic M3 receptor stimulation increases cigarette smoke-induced IL-8 secretion by human airway smooth muscle cells. European Respiratory Journal, 2009, 34, 1436-1443.	3.1	60
367	Safety of long-acting β -agonists: urgent need to clear the air remains. European Respiratory Journal, 2009, 33, 3-5.	3.1	42
368	T cells and eosinophils in bronchial smooth muscle cell death in asthma. Clinical and Experimental Allergy, 2009, 39, 845-855.	1.4	41
369	Pulmonary periarterial inflammation in fatal asthma. Clinical and Experimental Allergy, 2009, 39, 1499-1507.	1.4	30
370	Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 72-80.	2.7	92
371	Alternative mechanisms for tiotropium. Pulmonary Pharmacology and Therapeutics, 2009, 22, 533-542.	1.1	109
372	50 Years of psychological research on patients with COPD " Road to ruin or highway to heaven?. Respiratory Medicine, 2009, 103, 3-11.	1.3	40
373	Drop-out and attendance in pulmonary rehabilitation: The role of clinical and psychosocial variables. Respiratory Medicine, 2009, 103, 1564-1571.	1.3	168
374	Consistency of sputum eosinophilia in difficult-to-treat asthma: A 5-year follow-up study. Journal of Allergy and Clinical Immunology, 2009, 124, 615-617.e2.	1.5	106
375	Transaortic EUS-guided FNA in the diagnosis of lung tumors and lymph nodes. Gastrointestinal Endoscopy, 2009, 69, 345-349.	0.5	66
376	EUS-FNA for Mediastinal Restaging of Non Small Cell Lung Carcinoma (NSCLC). Gastrointestinal Endoscopy, 2009, 69, AB336.	0.5	0
377	EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopy. Lung Cancer, 2009, 63, 45-49.	0.9	150
378	An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer, 2009, 64, 166-170.	0.9	357

#	ARTICLE	IF	CITATIONS
379	Comparison of exhaled breath condensate pH using two commercially available devices in healthy controls, asthma and COPD patients. <i>Respiratory Research</i> , 2009, 10, 78.	1.4	44
380	A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor- α Blockade in Severe Persistent Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 549-558.	2.5	444
381	A vision statement on guideline development for respiratory disease: the example of COPD. <i>Lancet, The</i> , 2009, 373, 774-779.	6.3	70
382	Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. <i>Lancet, The</i> , 2009, 374, 695-703.	6.3	557
383	Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. <i>Lancet, The</i> , 2009, 374, 685-694.	6.3	717
384	Internet-Based Self-management Plus Education Compared With Usual Care in Asthma. <i>Annals of Internal Medicine</i> , 2009, 151, 110.	2.0	155
385	Effect of Fluticasone With and Without Salmeterol on Pulmonary Outcomes in Chronic Obstructive Pulmonary Disease. <i>Annals of Internal Medicine</i> , 2009, 151, 517.	2.0	166
386	EBUS-TBNA for the Clarification of PET Positive Intra-Thoracic Lymph Nodes – an International Multi-Centre Experience. <i>Journal of Thoracic Oncology</i> , 2009, 4, 44-48.	0.5	108
387	Is Asthma Control Test (ACT) the Best Measure To Quantify Asthma Control in Severe Not Controlled Patients?.. , 2009, , .		0
388	ARIA Update 2008: die allergische Rhinitis und ihr Einfluss auf das Asthma. <i>Allergologie</i> , 2009, 32, 306-319.	0.1	2
389	Lung Function and Bronchial Challenge Testing for the Allergist. , 2009, , 101-126.		0
390	Airway inflammation in obese and nonobese patients with difficult-to-treat asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 570-574.	2.7	163
391	Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 8-160.	2.7	3,827
392	Patients cured from craniopharyngioma or nonfunctioning pituitary macroadenoma (NFMA) suffer similarly from increased daytime somnolence despite normal sleep patterns compared to healthy controls. <i>Clinical Endocrinology</i> , 2008, 69, 769-774.	1.2	33
393	Expression of smooth muscle and extracellular matrix proteins in relation to airway function in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 1196-1202.	1.5	57
394	The Efficacy and Safety of Cilomilast in COPD. <i>Drugs</i> , 2008, 68, 3-57.	4.9	48
395	Sexuality in patients with asthma and COPD. <i>Respiratory Medicine</i> , 2008, 102, 198-204.	1.3	58
396	Somatostatin analog treatment is associated with an increased sleep latency in patients with long-term biochemical remission of acromegaly. <i>Growth Hormone and IGF Research</i> , 2008, 18, 446-453.	0.5	10

#	ARTICLE	IF	CITATIONS
397	COPD: more than respiratory â€œ Authors' reply. Lancet, The, 2008, 371, 28.	6.3	0
398	How Does Patientsâ€™ Quality of Life Guide Their Preferences Regarding Aspects of Asthma Therapy?. Patient, 2008, 1, 309-316.	1.1	6
399	Illness Perceptions and COPD: An Emerging Field for COPD Patient Management. Journal of Asthma, 2008, 45, 625-629.	0.9	72
400	Lung Cancer Staging With Minimally Invasive Endoscopic Techniques. JAMA - Journal of the American Medical Association, 2008, 299, 2509.	3.8	5
401	Value of chest radiography in phenotyping chronic obstructive pulmonary disease. European Respiratory Journal, 2008, 31, 509-515.	3.1	61
402	Outcomes for COPD pharmacological trials: from lung function to biomarkers. European Respiratory Journal, 2008, 31, 416-469.	3.1	732
403	Your 10,000 manuscripts. European Respiratory Journal, 2008, 32, 1425-1425.	3.1	2
404	Five good reasons to read (and cite) the ERJ. European Respiratory Journal, 2008, 31, 1-2.	3.1	23
405	Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies. European Respiratory Journal, 2008, 31, 70-77.	3.1	63
406	Complex chronic comorbidities of COPD. European Respiratory Journal, 2008, 31, 204-212.	3.1	538
407	Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. European Respiratory Journal, 2008, 32, 344-349.	3.1	110
408	Chicken or egg: physical activity in COPD revisited. European Respiratory Journal, 2008, 33, 227-229.	3.1	32
409	AvaliaÃ§Ã£o dos resultados nos ensaios clÃnicos na DPOC: Da funÃ§Ã£o pulmonar aos marcadores biolÃgicos. Revista Portuguesa De Pneumologia, 2008, 14, 579-583.	0.7	8
410	Illness Perceptions About Asthma Are Determinants of Outcome. Journal of Asthma, 2008, 45, 459-464.	0.9	73
411	Comparison of a Combination of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Moderate COPD. Chest, 2008, 134, 255-262.	0.4	111
412	Animal Models for Human Asthma: The Perspective of a Clinician. Current Drug Targets, 2008, 9, 438-442.	1.0	27
413	A Unique Spirometric Phenotype in COPD. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 432-433.	2.5	0
414	How does patients' quality of life guide their preferences regarding aspects of asthma therapy?: a patient-preference study using discrete-choice experiment methodology. Patient, 2008, 1, 309-16.	1.1	7

#	ARTICLE	IF	CITATIONS
415	Implementation of transesophageal ultrasound (EUS-FNA) for lung cancer staging. <i>Journal of Clinical Oncology</i> , 2008, 26, 7605-7605.	0.8	0
416	Illness Perceptions and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease. <i>Journal of Asthma</i> , 2007, 44, 575-581.	0.9	73
417	Small Airways Dysfunction and Neutrophilic Inflammation in Bronchial Biopsies and BAL in COPD. <i>Chest</i> , 2007, 131, 53-59.	0.4	55
418	Treating COPD â€” The TORCH Trial, P Values, and the Dodo. <i>New England Journal of Medicine</i> , 2007, 356, 851-854.	13.9	69
419	Why Respiratory Physicians Should Learn and Implement EUS-FNA. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 99-99.	2.5	18
420	Bronchial Inflammation and Airway Responses to Deep Inspiration in Asthma and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 121-128.	2.5	110
421	Update in Chronic Obstructive Pulmonary Disease 2006. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 1222-1232.	2.5	86
422	Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. <i>Thorax</i> , 2007, 62, 1081-1087.	2.7	254
423	Diaphragm plication in adult patients with diaphragm paralysis leads to long-term improvement of pulmonary function and level of dyspnea. <i>European Journal of Cardio-thoracic Surgery</i> , 2007, 32, 449-456.	0.6	105
424	A disintegrin and metalloprotease 33 and chronic obstructive pulmonary disease pathophysiology. <i>Thorax</i> , 2007, 62, 242-247.	2.7	63
425	Densitometry for assessment of effect of lung volume reduction surgery for emphysema. <i>European Respiratory Journal</i> , 2007, 29, 1138-1143.	3.1	43
426	Patient preferences for asthma therapy: a discrete choice experiment. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2007, 16, 241-248.	2.5	25
427	Predicting and evaluating response to omalizumab in patients with severe allergic asthma. <i>Respiratory Medicine</i> , 2007, 101, 1483-1492.	1.3	262
428	Epithelial differentiation is a determinant in the production of eotaxin-2 and -3 by bronchial epithelial cells in response to IL-4 and IL-13. <i>Molecular Immunology</i> , 2007, 44, 803-811.	1.0	71
429	From COPD to chronic systemic inflammatory syndrome?. <i>Lancet, The</i> , 2007, 370, 797-799.	6.3	522
430	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 532-555.	2.5	5,801
431	Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. <i>Lung Cancer</i> , 2007, 56, 25-33.	0.9	190
432	Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. <i>Respiratory Research</i> , 2007, 8, 85.	1.4	86

#	ARTICLE	IF	CITATIONS
433	Implementation of EUS-FNA for Lung Cancer Staging. <i>Gastrointestinal Endoscopy</i> , 2007, 65, AB119.	0.5	0
434	An electronic nose in the discrimination of patients with asthma and controls. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 856-862.	1.5	399
435	Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. <i>European Respiratory Journal</i> , 2007, 30, 467-471.	3.1	135
436	Exploring host-pathogen interactions at the epithelial surface: application of transcriptomics in lung biology. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007, 292, L367-L377.	1.3	8
437	Near-fatal asthma phenotype in the ENFUMOSA Cohort. <i>Clinical and Experimental Allergy</i> , 2007, 37, 552-557.	1.4	69
438	Burden of asthma in the hospital setting: an Australian analysis. <i>International Journal of Clinical Practice</i> , 2007, 61, 1884-1888.	0.8	15
439	Improving Dyspnea in Chronic Obstructive Pulmonary Disease: Optimal Treatment Strategies. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 270-275.	3.5	33
440	Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. <i>Lancet, The</i> , 2006, 368, 744-753.	6.3	368
441	Markers of exacerbation severity in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2006, 7, 74.	1.4	55
442	Increased number of B-cells in bronchial biopsies in COPD. <i>European Respiratory Journal</i> , 2006, 27, 60-64.	3.1	88
443	Anti-IgE Treatment Improves Lung Function In Patients With Mild Persistent Allergic Asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, S9.	1.5	1
444	The antimicrobial peptide LL-37 enhances IL-8 release by human airway smooth muscle cells. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 1328-1335.	1.5	66
445	Transesophageal Ultrasound and the Assessment of Tumour Invasion in Non-Small Cell Lung Cancer. <i>Gastrointestinal Endoscopy</i> , 2006, 63, AB259.	0.5	0
446	Markers of disease severity in chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2006, 19, 189-199.	1.1	127
447	Deficient alpha-1-antitrypsin phenotypes and persistent airflow limitation in severe asthma. <i>Respiratory Medicine</i> , 2006, 100, 1534-1539.	1.3	26
448	Mannose binding lectin (MBL) levels predict lung function decline in severe asthma. <i>European Respiratory Review</i> , 2006, 15, 224-225.	3.0	0
449	Poor asthma control in children: evidence from epidemiological surveys and implications for clinical practice. <i>International Journal of Clinical Practice</i> , 2006, 60, 321-334.	0.8	97
450	The effect of a single inhaled dose of a VLA-4 antagonist on allergen-induced airway responses and airway inflammation in patients with asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 1097-1103.	2.7	32

#	ARTICLE	IF	CITATIONS
451	Mechanisms of cell death induced by the neutrophil antimicrobial peptides α -defensins and LL-37. <i>Inflammation Research</i> , 2006, 55, 119-127.	1.6	109
452	Novel concepts of neuropeptide-based drug therapy: Vasoactive intestinal polypeptide and its receptors. <i>European Journal of Pharmacology</i> , 2006, 533, 182-194.	1.7	80
453	A molecular signature of epithelial host defense: comparative gene expression analysis of cultured bronchial epithelial cells and keratinocytes. <i>BMC Genomics</i> , 2006, 7, 9.	1.2	12
454	Budesonide/Formoterol in a Single Inhaler for Maintenance and Relief in Mild-to-Moderate Asthma. <i>Chest</i> , 2006, 129, 246-256.	0.4	228
455	Update in Chronic Obstructive Pulmonary Disease 2005. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1056-1065.	2.5	33
456	Guidelines for Chronic Obstructive Pulmonary Disease Treatment and Issues of Implementation. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 641-644.	3.5	21
457	State of the art lecture: EUS and EBUS in pulmonary medicine. <i>Endoscopy</i> , 2006, 38, 118-122.	1.0	43
458	Lung cancer patients with small nodes on CT - what's the next step?. <i>Endoscopy</i> , 2006, 38, 77-80.	1.0	4
459	What else can you expect at www.erj.ersjournals.com ?. <i>European Respiratory Journal</i> , 2006, 29, 1-3.	3.1	10
460	Cost of scheduled and unscheduled asthma management in seven European Union countries. <i>European Respiratory Review</i> , 2006, 15, 4-9.	3.0	39
461	Transbronchial and transoesophageal (ultrasound-guided) needle aspirations for the analysis of mediastinal lesions. <i>European Respiratory Journal</i> , 2006, 28, 1264-1275.	3.1	146
462	Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design. <i>European Respiratory Journal</i> , 2006, 27, 293-299.	3.1	32
463	Human Cathelicidin LL-37 Is a Chemoattractant for Eosinophils and Neutrophils That Acts via Formyl-Peptide Receptors. <i>International Archives of Allergy and Immunology</i> , 2006, 140, 103-112.	0.9	201
464	Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. <i>European Respiratory Journal</i> , 2006, 27, 951-956.	3.1	129
465	Differential distribution of inflammatory cells in large and small airways in smokers. <i>Journal of Clinical Pathology</i> , 2006, 60, 907-911.	1.0	50
466	Role of purinergic receptors in the activation of human airway smooth muscle cells by the antimicrobial peptide LL-37. <i>European Respiratory Review</i> , 2006, 15, 182-184.	3.0	0
467	Editing the ERJ: an observational study. <i>European Respiratory Journal</i> , 2006, 27, 1-2.	3.1	19
468	Host defense effector molecules in mucosal secretions. <i>FEMS Immunology and Medical Microbiology</i> , 2005, 45, 151-158.	2.7	42

#	ARTICLE	IF	CITATIONS
469	Transcriptional response of bronchial epithelial cells to <i>Pseudomonas aeruginosa</i> : identification of early mediators of host defense. <i>Physiological Genomics</i> , 2005, 21, 324-336.	1.0	77
470	Bronchial matrix and inflammation respond to inhaled steroids despite ongoing allergen exposure in asthma. <i>Clinical and Experimental Allergy</i> , 2005, 35, 1361-1369.	1.4	54
471	Small airways function and molecular markers in exhaled air in mild asthma. <i>Thorax</i> , 2005, 60, 639-644.	2.7	89
472	Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of sarcoidosis. <i>European Respiratory Journal</i> , 2005, 25, 405-409.	3.1	146
473	Risk factors of frequent exacerbations in difficult-to-treat asthma. <i>European Respiratory Journal</i> , 2005, 26, 812-818.	3.1	411
474	EUS: confusion about terminology and its consequences. <i>European Respiratory Journal</i> , 2005, 26, 182-183.	3.1	5
475	Obtaining optimal control in mild asthma: theory and practice. <i>Family Practice</i> , 2005, 22, 305-310.	0.8	12
476	Endoscopic Ultrasound Added to Mediastinoscopy for Preoperative Staging of Patients With Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 931.	3.8	165
477	Serving researchers, the impact factor and other conflicts of interest. <i>European Respiratory Journal</i> , 2005, 25, 3-5.	3.1	2
478	Endoscopic Ultrasoundâ€“Guided Fine-Needle Aspiration in the Diagnosis and Staging of Lung Cancer and Its Impact on Surgical Staging. <i>Journal of Clinical Oncology</i> , 2005, 23, 8357-8361.	0.8	185
479	Roflumilastâ€“an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. <i>Lancet, The</i> , 2005, 366, 563-571.	6.3	443
480	Roflumilast for chronic obstructive pulmonary disease. <i>Lancet, The</i> , 2005, 366, 1845.	6.3	3
481	Roflumilast for chronic obstructive pulmonary disease â€“ Author's reply. <i>Lancet, The</i> , 2005, 366, 1846-1847.	6.3	7
482	Endoscopic Ultrasound in Non-Small Cell Lung Cancer and its Impact on Surgical Staging. <i>Gastrointestinal Endoscopy</i> , 2005, 61, AB269.	0.5	0
483	P-347 Endoscopic ultrasound and the assessment of tumour invasion (T4). <i>Lung Cancer</i> , 2005, 49, S207.	0.9	0
484	The human cathelicidin LL-37: a multifunctional peptide involved in infection and inflammation in the lung. <i>Pulmonary Pharmacology and Therapeutics</i> , 2005, 18, 321-327.	1.1	74
485	Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2005, 99, 1511-1520.	1.3	91
486	Effects of cigarette smoke condensate on proliferation and wound closure of bronchial epithelial cells in vitro: role of glutathione. <i>Respiratory Research</i> , 2005, 6, 140.	1.4	110

#	ARTICLE	IF	CITATIONS
487	Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 779-785.	1.5	92
488	Expression of the anaphylatoxin receptors C3aR and C5aR is increased in fatal asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 1148-1154.	1.5	53
489	EUS-guided FNA of centrally located lung tumours following a non-diagnostic bronchoscopy. <i>Lung Cancer</i> , 2005, 48, 357-361.	0.9	96
490	Refractory Eosinophilic Airway Inflammation in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 601-605.	2.5	206
491	Refractory Eosinophilic Airway Inflammation in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 1385-1385.	2.5	1
492	Neutrophil Defensins Enhance Lung Epithelial Wound Closure and Mucin Gene Expression In Vitro. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2004, 30, 193-201.	1.4	148
493	A rare cause of Ortner's syndrome (cardiovascular hoarseness). <i>Thorax</i> , 2004, 59, 636-636.	2.7	17
494	Rapid, reliable and responsive: for whom?. <i>European Respiratory Journal</i> , 2004, 23, 1-2.	3.1	30
495	Histologic Patterns of Lung Infiltration of B-Cell, T-Cell, and Hodgkin Lymphomas. <i>American Journal of Clinical Pathology</i> , 2004, 121, 718-726.	0.4	22
496	Analysis of Subcarinal Lymph Nodes in (Suspected) Non-Small-Cell Lung Cancer after a Negative Transbronchial Needle Aspiration "What's Next?". <i>Respiration</i> , 2004, 71, 630-634.	1.2	15
497	Mechanisms of Bronchial Hyperreactivity in Asthma and Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2004, 1, 77-87.	3.5	76
498	Prednisolone response in patients with COPD * Authors' reply. <i>Thorax</i> , 2004, 59, 179-179.	2.7	5
499	Diagnosis of IPA in HIV: the role of the chest X-ray and radiologist. <i>European Radiology</i> , 2004, 14, 2030-2037.	2.3	12
500	Human neutrophil defensins and secretory leukocyte proteinase inhibitor in squamous metaplastic epithelium of bronchial airways. <i>Inflammation Research</i> , 2004, 53, 230-238.	1.6	24
501	Pharmacological basis for duration of effect: Formoterol and salmeterol versus short-acting β_2 -adrenoceptor agonists. <i>Lung</i> , 2004, 174, 1-22.	1.4	20
502	Lymphocytic inflammation in childhood bronchiolitis obliterans. <i>Pediatric Pulmonology</i> , 2004, 38, 233-239.	1.0	32
503	Outcome measures in COPD. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2004, 13, 177-178.	2.5	2
504	Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 40-47.	1.5	789

#	ARTICLE	IF	CITATIONS
505	TGF- β 2 differentially regulates TH2 cytokine-induced eotaxin and eotaxin-3 release by human airway smooth muscle cells. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 791-798.	1.5	39
506	Towards a minimally invasive staging strategy in NSCLC: analysis of PET positive mediastinal lesions by EUS-FNA. <i>Lung Cancer</i> , 2004, 44, 53-60.	0.9	107
507	Summary of recommendations for the design of clinical trials and the registration of drugs used in the treatment of asthma. <i>Respiratory Medicine</i> , 2004, 98, 479-487.	1.3	21
508	A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. <i>Respiratory Medicine</i> , 2004, 98, 1016-1024.	1.3	64
509	Diagnosing Sarcoidosis by Endoscopic Ultrasound Guided Fine Needle Aspiration (EUS-FNA). <i>Gastrointestinal Endoscopy</i> , 2004, 59, P216.	0.5	0
510	Burden and clinical features of chronic obstructive pulmonary disease (COPD). <i>Lancet, The</i> , 2004, 364, 613-620.	6.3	844
511	Refractory Eosinophilic Airway Inflammation in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 1385-1386.	2.5	4
512	Roflumilast Improves Lung Function and Quality of Life in Chronic Obstructive Pulmonary Disease. <i>Chest</i> , 2004, 126, 709S.	0.4	4
513	Proliferation and inflammation in bronchial epithelium after allergen in atopic asthmatics. <i>Clinical and Experimental Allergy</i> , 2003, 33, 905-911.	1.4	34
514	Mediastinal restaging: EUS-FNA offers a new perspective. <i>Lung Cancer</i> , 2003, 42, 311-318.	0.9	131
515	Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?. <i>Pulmonary Pharmacology and Therapeutics</i> , 2003, 16, 115-120.	1.1	50
516	Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). <i>Pulmonary Pharmacology and Therapeutics</i> , 2003, 16, 341-347.	1.1	30
517	You've got mail: erj@lumc.nl. <i>European Respiratory Journal</i> , 2003, 21, 1-2.	3.1	28
518	Combination therapy for chronic obstructive pulmonary disease: one size fits all?. <i>European Respiratory Journal</i> , 2003, 22, 874-875.	3.1	7
519	The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. <i>European Respiratory Journal</i> , 2003, 22, 470-477.	3.1	722
520	The Antimicrobial Peptide LL-37 Activates Innate Immunity at the Airway Epithelial Surface by Transactivation of the Epidermal Growth Factor Receptor. <i>Journal of Immunology</i> , 2003, 171, 6690-6696.	0.4	389
521	Predictors of Poor Asthma Control in European Adults. <i>Journal of Asthma</i> , 2003, 40, 803-813.	0.9	67
522	Correlation between annual change in health status and computer tomography derived lung density in subjects with α 1-antitrypsin deficiency. <i>Thorax</i> , 2003, 58, 1027-1030.	2.7	71

#	ARTICLE	IF	CITATIONS
523	Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. <i>European Respiratory Journal</i> , 2003, 22, 1-1.	3.1	948
524	Bilateral Cavitory Pulmonary Consolidations in a Patient Undergoing Allogeneic Bone Marrow Transplantation for Acute Leukemia. <i>Chest</i> , 2003, 123, 929-934.	0.4	8
525	Antiinflammatory Effects of the Phosphodiesterase-4 Inhibitor Cilomilast (Ariflo) in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 976-982.	2.5	207
526	Mediastinitis Caused by EUS-FNA of a Bronchogenic Cyst. <i>Endoscopy</i> , 2003, 35, 791-793.	1.0	94
527	Are Rhinovirus-induced Airway Responses in Asthma Aggravated by Chronic Allergen Exposure?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 1174-1180.	2.5	69
528	COPD: The role of primary care in effective diagnosis, treatment and management. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2003, 12, 16-20.	2.5	6
529	Studying human airway pharmacology in microsections: application of videomicroscopy. <i>European Respiratory Journal</i> , 2002, 19, 991-996.	3.1	7
530	Role of defensins in inflammatory lung disease. <i>Annals of Medicine</i> , 2002, 34, 96-101.	1.5	62
531	Assessment of Microvascular Leakage via Sputum Induction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1275-1279.	2.5	66
532	Rounded Mass in the Middle Lobe After Swan-Ganz Catheterization. <i>Chest</i> , 2002, 121, 261-263.	0.4	5
533	Asymptomatic Worsening of Airway Inflammation during Low-Dose Allergen Exposure in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 166, 294-300.	2.5	74
534	On Theophylline, Leukocytes, and Chicken Soup. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1351-1352.	2.5	3
535	Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2002, 2, 61-67.	1.1	13
536	Title is missing!. <i>Pharmaceutical Medicine</i> , 2002, 16, 115-127.	0.4	1
537	Chronic sinusitis in severe asthma is related to sputum eosinophilia. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 621-626.	1.5	281
538	Asthma control and differences in management practices across seven European countries. <i>Respiratory Medicine</i> , 2002, 96, 142-149.	1.3	146
539	Human neutrophil defensins induce lung epithelial cell proliferation in vitro. <i>Journal of Leukocyte Biology</i> , 2002, 72, 167-74.	1.5	102
540	Persistent airflow limitation in adult-onset nonatopic asthma is associated with serologic evidence of <i>Chlamydia pneumoniae</i> infection. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 449-454.	1.5	170

#	ARTICLE	IF	CITATIONS
541	Factors Associated with Persistent Airflow Limitation in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 744-748.	2.5	311
542	Formoterol in clinical practice—safety issues. Respiratory Medicine, 2001, 95, S21-S25.	1.3	12
543	A refugee with a supraclavicular lymph node An uncommon first presentation of carcinoma of the prostate. Netherlands Journal of Medicine, 2001, 58, 22-26.	0.6	2
544	Bronchodilators: An Overview. , 2001, 31, 54-59.		2
545	Chronic obstructive pulmonary disease (COPD): chronic bronchitis and emphysema. , 2001, , 631-633.		3
546	O Manejo Clínico da Asma em 1999: Uma Visão e a Realidade da Asma na Europa (Estudo AIRE). Revista Portuguesa De Pneumologia, 2001, 7, 169-171.	0.7	0
547	The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 364, 314-320.	1.4	25
548	Isolated airways from current smokers are hyper-responsive to histamine. Clinical and Experimental Allergy, 2001, 31, 1041-1047.	1.4	3
549	Pharmacological treatment of asthma today. European Respiratory Journal, 2001, 18, 34-40.	3.1	29
550	Initiation of Apoptosis by Actin Cytoskeletal Derangement in Human Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2001, 24, 282-294.	1.4	105
551	Sputum Induction in Severe Asthma by a Standardized Protocol. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 749-753.	2.5	54
552	Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. European Respiratory Journal, 2000, 16, 802-807.	3.1	858
553	Serum immunoglobulin E levels predict human airway reactivity in vitro. Clinical and Experimental Allergy, 2000, 30, 233-241.	1.4	25
554	Involvement of protein tyrosine kinases in activation of human eosinophils by platelet-activating factor. Immunology, 2000, 100, 231-237.	2.0	9
555	The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C4-induced contractions in passively sensitized human airways. British Journal of Pharmacology, 2000, 131, 1607-1618.	2.7	75
556	The effect of the enantiomers of formoterol on inherent and induced tone in guinea-pig trachea and human bronchus. Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, 361, 405-409.	1.4	25
557	Up-regulation of human eosinophil leukotriene C 4 generation through contact with bronchial epithelial cells. Inflammation Research, 2000, 49, 236-239.	1.6	10
558	Fas cross-linking induces apoptosis in human airway smooth muscle cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 278, L618-L624.	1.3	41

#	ARTICLE	IF	CITATIONS
559	Leukotrienes as Targets for Treatment of Asthma and Other Diseases. American Journal of Respiratory and Critical Care Medicine, 2000, 161, S1-S1.	2.5	20
560	The Role of Leukotrienes in the Regulation of Tone and Responsiveness in Isolated Human Airways. American Journal of Respiratory and Critical Care Medicine, 2000, 161, S62-S67.	2.5	25
561	Immune mechanisms of smooth muscle hyperreactivity in asthma. Journal of Allergy and Clinical Immunology, 2000, 105, 673-682.	1.5	44
562	Effect of proinflammatory cytokines on interleukin-8 mRNA expression and protein production by isolated human alveolar epithelial cells type II in primary culture. European Cytokine Network, 2000, 11, 618-25.	1.1	33
563	Augmentation of eosinophil degranulation and LTC ₄ secretion by integrin-mediated endothelial cell adhesion. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 277, L802-L810.	1.3	8
564	Role of Very Late Adhesion Integrins in Mediating Repair of Human Airway Epithelial Cell Monolayers after Mechanical Injury. American Journal of Respiratory Cell and Molecular Biology, 1999, 20, 787-796.	1.4	63
565	Exhaled nitric oxide in COPD: glancing through a smoke screen. Thorax, 1999, 54, 565-567.	2.7	29
566	Characterization of cell surface lectin-binding patterns of human airway epithelium. The Histochemical Journal, 1999, 31, 145-151.	0.6	51
567	Defensins: Key players or bystanders in infection, injury, and repair in the lung? Journal of Allergy and Clinical Immunology, 1999, 104, 1131-1138.	1.5	159
568	Passive sensitization of human airways increases responsiveness to leukotriene C ₄ . European Respiratory Journal, 1999, 14, 315-319.	3.1	42
569	The relevance of resting tension to responsiveness and inherent tone of human bronchial smooth muscle. British Journal of Pharmacology, 1998, 123, 694-700.	2.7	23
570	Histamine hypersensitivity induced by passive sensitization of human bronchus: effect of serum IgE depletion. Clinical and Experimental Allergy, 1998, 28, 679-685.	1.4	25
571	Effects of a Selective PDE4 Inhibitor, D-22888, on Human Airways and Eosinophils in vitro and Late Phase Allergic Pulmonary Eosinophilia in Guinea Pigs. Pulmonary Pharmacology and Therapeutics, 1998, 11, 13-21.	1.1	12
572	Cyclic Nucleotide Phosphodiesterase in Human Bronchial Epithelial Cells: Characterization of Isoenzymes and Functional Effects of PDE Inhibitors. Pulmonary Pharmacology and Therapeutics, 1998, 11, 47-56.	1.1	47
573	Inhibition of Human Airway Sensitization by a Novel Monoclonal Anti-IgE Antibody, 17-9. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1429-1435.	2.5	34
574	Protein Kinase C Inhibition Enhances Platelet-activating Factor-induced Eicosanoid Production in Human Eosinophils. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 136-144.	1.4	31
575	Mechanisms of Immune Sensitization of Human Bronchus. American Journal of Respiratory and Critical Care Medicine, 1998, 158, S161-S170.	2.5	24
576	Expression of Fas (CD95) and FasL (CD95L) in Human Airway Epithelium. American Journal of Respiratory Cell and Molecular Biology, 1998, 19, 537-542.	1.4	86

#	ARTICLE	IF	CITATIONS
577	Leukotrienes in induced airway obstruction. , 1998, , 73-77.		0
578	Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. European Respiratory Journal, 1998, 11, 617-23.	3.1	34
579	Role of IgE in hyperresponsiveness induced by passive sensitization of human airways.. American Journal of Respiratory and Critical Care Medicine, 1997, 155, 839-844.	2.5	57
580	Distribution of inhaled fluticasone propionate between human lung tissue and serum <l>in vivo</l>. European Respiratory Journal, 1997, 10, 1496-1499.	3.1	124
581	Conservation of bronchiolar wall area during constriction and dilation of human airways. Journal of Applied Physiology, 1997, 82, 954-958.	1.2	7
582	Passive sensitization of human airways induces myogenic contractile responses in vitro. Journal of Applied Physiology, 1997, 83, 1276-1281.	1.2	42
583	Inherent tone of human bronchus: role of eicosanoids and the epithelium. British Journal of Pharmacology, 1997, 121, 1099-1104.	2.7	26
584	Augmentation of human neutrophil and alveolar macrophage LTB4 production by N -acetylcysteine: role of hydrogen peroxide. British Journal of Pharmacology, 1997, 122, 758-764.	2.7	21
585	Eosinophil VLA-4 binding to fibronectin augments bronchial narrowing through 5-lipoxygenase activation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1996, 270, L587-L594.	1.3	16
586	Reproducibility of airway response to inhaled bradykinin and effect of the neurokinin receptor antagonist FK-24 in asthmatic subjects. European Journal of Clinical Pharmacology, 1996, 50, 269-273.	0.8	25
587	Isolated, Electrically-stimulated Airway Preparationsâ€™ Their Use in Determining ² -Adrenoceptor Agonist Activity. Pulmonary Pharmacology, 1996, 9, 107-117.	0.5	10
588	Effects of Theophylline and Non-selective Xanthine Derivatives on PDE Isoenzymes and Cellular Function. , 1996, , 41-64.		9
589	Relationship between bronchoalveolar lavage neutrophil numbers and lavage fluid elastase and antielastase activities. Lung, 1995, 173, 165-75.	1.4	3
590	Alveolar macrophages from bronchoalveolar lavage of patients with pulmonary histiocytosis X: Determination of phenotypic and functional changes. Lung, 1995, 173, 187-95.	1.4	12
591	Further evidence that tachykinin-induced contraction of human isolated bronchus is mediated only by NK2-receptors. Neuropeptides, 1995, 29, 281-292.	0.9	43
592	Assessment of agonist- and cell-mediated responses in airway microsections by computerized videomicrometry. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1995, 268, L519-L525.	1.3	6
593	Migration and proliferation of guinea pig and human airway epithelial cells in response to tachykinins. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1995, 269, L119-L126.	1.3	20
594	Hydrogen peroxide contracts human airways in vitro: role of epithelium. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1995, 269, L332-L338.	1.3	26

#	ARTICLE	IF	CITATIONS
595	Antagonism of β_2 -adrenoceptor-mediated relaxations of human bronchial smooth muscle by carbachol. <i>European Journal of Pharmacology</i> , 1995, 275, 307-310.	1.7	22
596	Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. <i>European Respiratory Journal</i> , 1995, 8, 637-42.	3.1	98
597	Contraction of human bronchial smooth muscle caused by activated human eosinophils. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1994, 267, L326-L334.	1.3	19
598	Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1994, 266, L536-L543.	1.3	71
599	Passive sensitization of human bronchi augments smooth muscle shortening velocity and capacity. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1994, 267, L218-L222.	1.3	57
600	Theophylline suppresses human alveolar macrophage respiratory burst through phosphodiesterase inhibition.. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1994, 10, 565-572.	1.4	65
601	Cyclic nucleotide phosphodiesterases in the human lung. <i>Lung</i> , 1994, 172, 129-46.	1.4	39
602	Characterisation of the endothelin receptor mediating contraction of human pulmonary artery using BQ123 and Ro 46-2005. <i>European Journal of Pharmacology</i> , 1994, 260, 221-225.	1.7	28
603	Migration of human and guinea pig airway epithelial cells in response to calcitonin gene-related peptide.. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1994, 11, 181-187.	1.4	30
604	Why are long-acting beta-adrenoceptor agonists long-acting?. <i>European Respiratory Journal</i> , 1994, 7, 569-578.	3.1	216
605	Inhibitory effects of sulfonated shale oil fractions on the oxidative burst and Ca^{++} mobilization in stimulated macrophages. <i>Arzneimittelforschung</i> , 1994, 44, 166-70.	0.5	3
606	Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1994, 271, 1167-74.	1.3	67
607	The effect of 10, 50 and 200 mug inhaled fenoterol on exercise induced asthma. <i>Clinical and Experimental Allergy</i> , 1993, 23, 440-445.	1.4	7
608	Salmeterol is a competitive antagonist at β_2 -adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils. <i>European Journal of Pharmacology</i> , 1993, 231, 305-308.	1.7	45
609	Effects of β_2 -adrenoceptor agonists in human bronchial smooth muscle. <i>British Journal of Pharmacology</i> , 1993, 110, 1112-1116.	2.7	63
610	Comparison of the Effects of Salmeterol and Formoterol on Airway Tone and Responsiveness over 24 Hours in Bronchial Asthma. <i>The American Review of Respiratory Disease</i> , 1993, 147, 1436-1441.	2.9	157
611	Increased LTB4 Metabolites and PGD2 In BAL Fluid after Methacholine Challenge in Asthmatic Subjects. <i>Chest</i> , 1993, 104, A-21.	0.4	0
612	Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1993, 264, L458-L464.	1.3	42

#	ARTICLE	IF	CITATIONS
613	The protective effect of low-dose inhaled fenoterol against methacholine and exercise-induced bronchoconstriction in asthma: A dose-response study. <i>Journal of Allergy and Clinical Immunology</i> , 1992, 90, 846-851.	1.5	4
614	Activation of guinea pig eosinophil respiratory burst by leukotriene B ₄ : role of protein kinase C. <i>Fundamental and Clinical Pharmacology</i> , 1992, 6, 353-358.	1.0	4
615	Variability in Aerosol Output of the DeVilbiss 646 Jet Nebulizer. <i>Chest</i> , 1992, 102, 1636.	0.4	7
616	Low dose fenoterol aerosol protects against histamine-induced bronchoconstriction in mild asthmatics: a dose response study. <i>Clinical and Experimental Allergy</i> , 1992, 22, 690-693.	1.4	9
617	Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours. <i>European Journal of Clinical Pharmacology</i> , 1992, 43, 591-595.	0.8	23
618	Neutrophil influx into guinea pig airway lumen during cholinergic and non-cholinergic bronchoconstriction. <i>Acta Physiologica Scandinavica</i> , 1992, 144, 101-106.	2.3	17
619	Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by β -type IV-selective PDE inhibitors. <i>British Journal of Pharmacology</i> , 1991, 103, 1339-1346.	2.7	131
620	The challenge of long-acting β_2 -adrenoceptor agonists. <i>Respiratory Medicine</i> , 1991, 85, 5-9.	1.3	19
621	Therapy of bronchial hyper-responsiveness. <i>Clinical and Experimental Allergy</i> , 1991, 21, 379-389.	1.4	6
622	Association of Airway Eosinophilia with Small Airway Dysfunction in Patients with Mild and at Risk for COPD. <i>International Journal of COPD</i> , 0, Volume 17, 1403-1408.	0.9	2